Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-06349-0
Abstract: Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) strategies with proven in vivo efficacy rely on antiretroviral drugs, creating the potential for drug resistance and complicated treatment options in individuals who become infected. Moreover, on-demand products… read more here.
Keywords: grft; fast dissolving; carrageenan fast; hsv hpv ... See more keywords
Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01084-19
Abstract: Griffithsin (Grft) is an antiviral lectin that has been shown to potently inhibit HIV-1 by binding high-mannose N-linked glycosylation sites on HIV-1 gp120. A key factor for Grft potency is glycosylation at N295 of gp120,… read more here.
Keywords: broadly neutralizing; glycosylation; potency; gp120 ... See more keywords
Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0261775
Abstract: HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT’s preclinical safety, lack of systemic absorption after vaginal administration in animal studies,… read more here.
Keywords: randomized placebo; placebo controlled; hiv; first human ... See more keywords